UM

Browse/Search Results:  1-9 of 9 Help

Selected(0)Clear Items/Page:    Sort:
Nicotinamide Promotes Cell Survival and Differentiation as Kinase Inhibitor in Human Pluripotent Stem Cells Journal article
Stem Cell Reports, 2018,Volume: 11,Issue: 6,Page: 1347-1356
Authors:  Meng Y.;  Ren Z.;  Xu F.;  Zhou X.;  Song C.;  Wang V.Y.-F.;  Liu W.;  Lu L.;  Thomson J.A.;  Chen G.
Favorite | View/Download:15/0 | TC[WOS]:11 TC[Scopus]:13 | Submit date:2019/01/15
cell differentiation  cell survival  human pluripotent stem cell  kinase inhibitor  nicotinamide  
Inhibition of pyruvate dehydrogenase kinase 1 enhances the anti-cancer effect of EGFR tyrosine kinase inhibitors in non-small cell lung cancer Journal article
EUROPEAN JOURNAL OF PHARMACOLOGY, 2018,Volume: 838,Page: 41-52
Authors:  Yang, Zheng;  Zhang, Shao-Lin;  Hu, Xiaohui;  Tam, Kin Yip
Favorite | View/Download:35/0 | TC[WOS]:3 TC[Scopus]:4 | Submit date:2018/10/30
Dichloroacetophenone  Epidermal Growth Factor Receptor  Tyrosine Kinase Inhibitor  Synergism  Hypoxia  Oxidative Phosphorylation  
The CDK1 inhibitor RO3306 improves the response of BRCA-proficient breast cancer cells to PARP inhibition Journal article
International Journal of Oncology, 2014,Volume: 44,Issue: 3,Page: 735
Authors:  Xia Q.;  Cai Y.;  Peng R.;  Wu G.;  Shi Y.;  Jiang W.
Favorite | View/Download:14/0 | TC[WOS]:17 TC[Scopus]:23 | Submit date:2018/10/30
BRCA1  Breast cancer  Cyclin-dependent kinase 1  Poly (ADP-ribose) polymerase inhibitor  
The effect of mild and moderate hepatic impairment on the pharmacokinetics of tofacitinib, an orally active Janus kinase inhibitor Journal article
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2014,Volume: 3,Issue: 6,Page: 421-427
Authors:  Lawendy, N.;  Lamba, M.;  Chan, G.;  Wang, R.;  Alvey, C. W.;  Krishnaswami,S.
Favorite | View/Download:4/0 | TC[WOS]:5 TC[Scopus]:7 | Submit date:2020/01/06
Pharmacokinetics  Clinical Pharmacology  Hepatic Impairment  Janus Kinase Inhibitor  Tofacitinib  
Arylphthalazines as potent, and orally bioavailable inhibitors of VEGFR-2 Journal article
Bioorganic and Medicinal Chemistry, 2009,Volume: 17,Issue: 2,Page: 731-740
Authors:  Duncton M.A.J.;  Piatnitski Chekler E.L.;  Katoch-Rouse R.;  Sherman D.;  Wong W.C.;  Smith II L.M.;  Kawakami J.K.;  Kiselyov A.S.;  Milligan D.L.;  Balagtas C.;  Hadari Y.R.;  Wang Y.;  Patel S.N.;  Rolster R.L.;  Tonra J.R.;  Surguladze D.;  Mitelman S.;  Kussie P.;  Bohlen P.;  Doody J.F.
Favorite | View/Download:8/0 | TC[WOS]:31 TC[Scopus]:33 | Submit date:2019/01/16
Angiogenesis  Arylphthalazine  Inhibitor  KDR  Kinase  Phthalazine  VEGFR-2  
The discovery of AZD5597, a potent imidazole pyrimidine amide CDK inhibitor suitable for intravenous dosing Journal article
Bioorganic and Medicinal Chemistry Letters, 2008,Volume: 18,Issue: 24,Page: 6369-6373
Authors:  Jones C.D.;  Andrews D.M.;  Barker A.J.;  Blades K.;  Daunt P.;  East S.;  Geh C.;  Graham M.A.;  Johnson K.M.;  Loddick S.A.;  McFarland H.M.;  McGregor A.;  Moss L.;  Rudge D.A.;  Simpson P.B.;  Swain M.L.;  Tam K.Y.;  Tucker J.A.;  Walker M.
Favorite | View/Download:10/0 | TC[WOS]:32 TC[Scopus]:34 | Submit date:2018/12/18
Anti-cancer  Cdk  Cell Cycle  Cyclin-dependent Kinase  Imidazole Amide  Kinase  Kinase Inhibitor  
Synthesis and evaluation of heteroaryl-ketone derivatives as a novel class of VEGFR-2 inhibitors Journal article
Bioorganic and Medicinal Chemistry Letters, 2008,Volume: 18,Issue: 15,Page: 4344-4347
Authors:  Piatnitski Chekler E.L.;  Katoch-Rouse R.;  Kiselyov A.S.;  Sherman D.;  Ouyang X.;  Kim K.;  Wang Y.;  Hadari Y.R.;  Doody J.F.
Favorite | View/Download:7/0 | TC[WOS]:9 TC[Scopus]:10 | Submit date:2019/01/16
Angiogenesis  Kinase inhibitor  Vascular endothelial growth factor  
Novel tricyclic azepine derivatives: Biological evaluation of pyrimido[4,5-b]-1,4-benzoxazepines, thiazepines, and diazepines as inhibitors of the epidermal growth factor receptor tyrosine kinase Journal article
Bioorganic and Medicinal Chemistry Letters, 2006,Volume: 16,Issue: 19,Page: 5102-5106
Authors:  Smith II L.;  Wong W.C.;  Kiselyov A.S.;  Burdzovic-Wizemann S.;  Mao Y.;  Xu Y.;  Duncton M.A.J.;  Kim K.;  Piatnitski E.L.;  Doody J.F.;  Wang Y.;  Rosler R.L.;  Milligan D.;  Columbus J.;  Balagtas C.;  Lee S.P.;  Konovalov A.;  Hadari Y.R.
Favorite | View/Download:5/0 | TC[WOS]:29 TC[Scopus]:32 | Submit date:2019/01/16
Diazepine  Epidermal growth factor receptor  Kinase inhibitor  Oxazepine  Thiazepine  
Tricyclic azepine derivatives: Pyrimido[4,5-b]-1,4-benzoxazepines as a novel class of epidermal growth factor receptor kinase inhibitors Journal article
Bioorganic and Medicinal Chemistry Letters, 2006,Volume: 16,Issue: 6,Page: 1643-1646
Authors:  Smith II L.;  Piatnitski E.L.;  Kiselyov A.S.;  Ouyang X.;  Chen X.;  Burdzovic-Wizemann S.;  Xu Y.;  Wang Y.;  Rosler R.L.;  Patel S.N.;  Chiang H.-H.;  Milligan D.L.;  Columbus J.;  Wong W.C.;  Doody J.F.;  Hadari Y.R.
Favorite | View/Download:9/0 | TC[WOS]:18 TC[Scopus]:17 | Submit date:2019/01/16
Benzoxazepine  Epidermal growth factor receptor  Kinase inhibitor  Kinase selectivity